Stacy L. Vezina
@Finepoint Capital Lp
Latest period2024 - Q3ReportedManaged Assets$1.376BTotal holdings26
Assets growth rate290.61%Assets growth rate (2-Q avg)140.48%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Finepoint Capital Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 26 positions.
Assets under management
The assets under management (AUM) of Finepoint Capital Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.376B in assets, with a quarterly growth rate of 290.61% and a 2-quarter average growth rate of 140.48%. The portfolio is managed by Stacy L. Vezina, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
SRPTSarepta Therapeutics Inc
| 1.22% | $16.677M 133,535 shares@ $124.89 avg price | Increased 0.53% |
GLPGGalapagos Nv
| 1.17% | $16.058M 557,762 shares@ $28.8 avg price | Increased 2.77% |
ARVNArvinas Inc
| 1.03% | $14.147M 574,378 shares@ $24.63 avg price | |
ACADAcadia Pharmaceuticals Inc
| 1.02% | $13.925M 905,384 shares@ $15.39 avg price | |
CYTKCytokinetics Inc
| 0.99% | $13.541M 256,449 shares@ $52.8 avg price | |
RLAYRelay Therapeutics Inc
| 0.84% | $11.513M 1.626M shares@ $7.09 avg price | Increased 1.3% |
PRTAProthena Corp Plc
| 0.53% | $7.252M 433,471 shares@ $16.74 avg price | |
SLDBSolid Biosciences Inc
| 0.49% | $6.7M 961,251 shares@ $6.97 avg price | |
EYPTEyepoint Pharmaceuticals Inc
| 0.42% | $5.652M 707,404 shares@ $8.0 avg price | |
IVCPWSwiftmerge Acquisition Corp
| 0.01% | $39,200 490,000 shares@ $0.08 avg price |